NCP Cross
NCP Cross
Email verificata su
Citata da
Citata da
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome
J Cools, DJ DeAngelo, J Gotlib, EH Stover, RD Legare, J Cortes, J Kutok, ...
New England Journal of Medicine 348 (13), 1201-1214, 2003
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2
J Nangalia, CE Massie, EJ Baxter, FL Nice, G Gundem, DC Wedge, ...
New England Journal of Medicine 369 (25), 2391-2405, 2013
Clinical and biological implications of driver mutations in myelodysplastic syndromes
E Papaemmanuil, M Gerstung, L Malcovati, S Tauro, G Gundem, ...
Blood, The Journal of the American Society of Hematology 122 (22), 3616-3627, 2013
The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms
JD Khoury, E Solary, O Abla, Y Akkari, R Alaggio, JF Apperley, R Bejar, ...
leukemia 36 (7), 1703-1719, 2022
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABLá…
T Hughes, M Deininger, A Hochhaus, S Branford, J Radich, J Kaeda, ...
Blood 108 (1), 28-37, 2006
Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
E Papaemmanuil, M Cazzola, J Boultwood, L Malcovati, P Vyas, D Bowen, ...
New England Journal of Medicine 365 (15), 1384-1395, 2011
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
T Ernst, AJ Chase, J Score, CE Hidalgo-Curtis, C Bryant, AV Jones, ...
Nature genetics 42 (8), 722-726, 2010
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
A Hochhaus, S Kreil, AS Corbin, P La Rosee, MC MŘller, T Lahaye, ...
Leukemia 16 (11), 2190-2196, 2002
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
AV Jones, S Kreil, K Zoi, K Waghorn, C Curtis, L Zhang, J Score, R Seear, ...
Blood 106 (6), 2162-2168, 2005
Mutations and prognosis in primary myelofibrosis
AM Vannucchi, TL Lasho, P Guglielmelli, F Biamonte, A Pardanani, ...
Leukemia 27 (9), 1861-1869, 2013
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta
JF Apperley, M Gardembas, JV Melo, R Russell-Jones, BJ Bain, EJ Baxter, ...
New England Journal of Medicine 347 (7), 481-487, 2002
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of Europeaná…
S Soverini, A Hochhaus, FE Nicolini, F Gruber, T Lange, G Saglio, F Pane, ...
Blood, The Journal of the American Society of Hematology 118 (5), 1208-1215, 2011
Aberrations of EZH2 in Cancer
A Chase, NCP Cross
Clinical cancer research 17 (9), 2613-2618, 2011
Prognostic score including gene mutations in chronic myelomonocytic leukemia
R Itzykson, O Kosmider, A Renneville, V Gelsi-Boyer, M Meggendorfer, ...
Journal of clinical oncology 31 (19), 2428-2436, 2013
Standardized definitions of molecular response in chronic myeloid leukemia
NCP Cross, HE White, MC MŘller, G Saglio, A Hochhaus
Leukemia 26 (10), 2172-2175, 2012
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms
AV Jones, A Chase, RT Silver, D Oscier, K Zoi, YL Wang, H Cario, ...
Nature genetics 41 (4), 446-449, 2009
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patientá…
S Branford, L Fletcher, NCP Cross, MC MŘller, A Hochhaus, DW Kim, ...
Blood, The Journal of the American Society of Hematology 112 (8), 3330-3338, 2008
Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation
NC Cross, L Feng, A Chase, J Bungey, TP Hughes, JM Goldman
Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms
FH Grand, CE Hidalgo-Curtis, T Ernst, K Zoi, C Zoi, C McGuire, S Kreil, ...
Blood, The Journal of the American Society of Hematology 113 (24), 6182-6192, 2009
CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy
A Pardanani, RP Ketterling, SR Brockman, HC Flynn, SF Paternoster, ...
Blood 102 (9), 3093-3096, 2003
Il sistema al momento non pu˛ eseguire l'operazione. Riprova pi¨ tardi.
Articoli 1–20